Drugs / NK cells
Trials 49
News releases announcing trial results or a regulatory action · 118
| Date | Issuer | Release |
|---|---|---|
| 2026-09-25 | C4 Therapeutics, Inc. | Results C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting c4therapeutics.com ↗
In 62 heavily pre-treated RRMM patients across the once-daily (QD) dose levels, cemsidomide demonstrated coordinated activation of T cells, including CD8+ T cells, and functional reprogramming of natural killer (NK) cells. |
| 2026-03-13 | ImmunityBio, Inc. | Results ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors immunitybio.com ↗ |
| 2025-11-03 | Oncopeptides AB | Results Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH oncopeptides.com ↗
In preclinical models, the combination demonstrated synergistic anti-myeloma activity, efficient tumor cell lysis, and reduced cytokine release compared to existing T-cell-based strategies, supporting the potential of this new modality as a novel immunotherapeutic approach for relapsed or refractory multiple myeloma. |
| 2025-07-28 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025 nkgenbiotech.com ↗
Troculeucel was shown to internalize and digest amyloid and α-synuclein proteins in vitro and to improve CSF levels of amyloid, α-synuclein, and p-tau in Phase 1 patients in a largely dose-dependent manner. |
| 2025-07-21 | NKGen Biotech, Inc. | Regulatory NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases nkgenbiotech.com ↗ |
| 2025-06-23 | Purple Biotech Ltd. | Results Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress purple-biotech.com ↗
Our data demonstrate that the NKG2A arm in CAPTN-3 TCE synergizes with the anti-CD3 arm to induce significant cytotoxic effects against solid tumor cells. |
| 2025-05-19 | GT Biopharma, Inc. | Results GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals gtbiopharma.com ↗
Based on multiple assays of various blood biomarkers, both patients in Cohort 1 have shown early evidence of increased immunologic activity, supporting GTB-3650’s ability to activate endogenous NK cells and induce NK cell expansion. |
| 2025-02-13 | NKGen Biotech, Inc. | Results NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease nkgenbiotech.com ↗
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. |
| 2024-11-08 | Synthekine | Results Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting synthekine.com ↗
Our data reinforces STK-012’s unique mechanism of action, as demonstrated by selective expansion of antigen activated T cells without broad expansion of other lymphocytes including NK cells. |
| 2024-11-07 | Coeptis Therapeutics | Results Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development coeptis.com ↗
Results from the clinical trial demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections. |
| 2024-10-29 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference nkgenbiotech.com ↗
Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are detectable up to 10 years before dementia symptoms appear according to recent reports. |
| 2024-10-16 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT’s 2024 Advancing Gene and Cell Therapies for Cancer Conference phiopharma.com ↗
PH-894 treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability. |
| 2024-09-12 | NKGen Biotech, Inc. | Results NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial nkgenbiotech.com ↗
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced promising early interim data from the Phase 1 cohort and the dosing of the first Phase 2 patient in the Phase 1/2a clinical trial of troculeucel, NKGen’s cryopreserved autologous enhanced NK cell therapy for the treatment of moderate Alzheimer’s disease (“AD”). |
| 2024-07-30 | NKGen Biotech, Inc. | Results NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference nkgenbiotech.com ↗
SNK01 treatment appears to stabilize or improve cognitive function and reduce α-synuclein levels in CSF in addition to improving previously reported amyloid, tau, and neuroinflammatory markers (GFAP, NfL, YKL-40) in the majority of patients. |
| 2024-07-23 | Inmune Bio, Inc. | Results INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer inmunebio.com ↗
The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmune TM priming, show increased cytotoxicity against multiple tumor types, offering promising potential for cancer immunotherapy. |
| 2024-07-18 | NKGen Biotech, Inc. | Results NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference nkgenbiotech.com ↗
NKGen will present data on SNK01’s ability to reduce α-synuclein in Alzheimer’s patients, which is significant given that α-synuclein has been shown to correlate with worse cognitive function in Alzheimer’s disease. |
| 2024-06-14 | Wugen, Inc. | Results Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress wugen.com ↗
WU-NK-101 is an Off-The-Shelf Memory NK Cell with a Time-Resilient, Anti-Tumor Phenotype that can be Detected in R/R AML Patient PBMC After Infusion |
| 2024-06-12 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 nkgenbiotech.com ↗
Dr. Song also provided an update on the Company’s initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. |
| 2024-05-23 | NKGen Biotech, Inc. | Results NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting nkgenbiotech.com ↗
In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02. |
| 2024-05-20 | NKGen Biotech, Inc. | Results NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease nkgenbiotech.com ↗
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. |
| 2024-05-16 | Mendus | Results Mendus announces presentation of multiple abstracts during the 2024 CIMT Annual Meeting mendus.com ↗
The expanded memory NK cells exhibit strong tumor cell killing capacity, particularly in combination with tumor-specific antibodies. |
| 2024-05-15 | Senti Biosciences | Results Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits sentibio.com ↗
Logic-gated NK cells kill leukemic stem cells and blasts, not healthy stem cells |
| 2024-04-29 | NKGen Biotech, Inc. | Regulatory NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease nkgenbiotech.com ↗
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for SNK01 NK cell therapy for the treatment of Parkinson’s disease (“PD”). |
| 2024-04-25 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit nkgenbiotech.com ↗
SNK01 autologous NK cell therapy demonstrated a positive effect on improving cerebral spinal fluid (“CSF”) and plasma levels of Tau, amyloid, and alpha-synuclein proteins in Alzheimer’s patients suggesting a potential larger application in the treatment of other neurodegenerative diseases associated with these proteins. |
| 2024-04-08 | Celularity Incorporated | Results Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells celularity.com ↗
The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024. |
| 2024-03-25 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference nkgenbiotech.com ↗
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. |
| 2024-03-21 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies phiopharma.com ↗
Cytotoxic activity of NK cells against K562 (Chronic Myelogenous Leukemia) cancer cells was also increased. |
| 2023-12-27 | NKGen Biotech, Inc. | Regulatory NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease nkgenbiotech.com ↗
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients. |
| 2023-12-11 | Nektar Therapeutics | Results Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting nektar.com ↗
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65 th American Society of Hematology (ASH) Annual Meeting demonstrating that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant BL cells and significantly improved the survival of mice xenografted with Raji-4RH compared to controls. |
| 2023-12-01 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 日서 GMP 허가 완료..."알츠하이머 치료길 열렸다" nkgenbiotechkorea.com ↗
엔케이맥스는 일본 후생노동성으로부터 자사의 NK세포치료제(SNK01) 국내 제조시설의 의약품제조(GMP) 허가를 받았다고 16일 밝혔다. |
| 2023-11-03 | Coherus Oncology, Inc. | Results Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) coherus.com ↗
Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors |
| 2023-10-26 | NKGen Biotech, Inc. | Results NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference nkgenbiotech.com ↗
SNK01 is well-tolerated and appears to reduce both proteins (pTau181 and Aβ42/40) and neuroinflammation (GFAP) among trial patients,” said Paul Y. Song, M.D., CEO of NKGen Biotech. |
| 2023-10-24 | NKGen Biotech, Inc. | Regulatory NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease nkgenbiotech.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for SNK01 natural killer (NK) cell therapy for treatment of moderate Alzheimer’s Disease (AD). |
| 2023-10-17 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023 nkgenbiotech.com ↗ |
| 2023-07-27 | NKMAX Co., Ltd. | Results 엔케이맥스, ASCO 초록 공개…TKI 불응성 비소세포폐암 'DCR 100%' nkgenbiotechkorea.com ↗
투여 결과 12명의 환자 중 부분관해(PR) 3명과 안정병변(SD) 9명으로 DCR 100%의 유의미한 유효성이 확인됐다. |
| 2023-07-17 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference nkgenbiotech.com ↗ |
| 2023-06-10 | Nkarta, Inc. | Results Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma nkartatx.com ↗
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study |
| 2023-06-09 | Wugen, Inc. | Results Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress wugen.com ↗
The infusion of ML-NK cells was associated with modulation of the AML tumor microenvironment and engagement of the endogenous adaptive immune response. |
| 2023-06-05 | NKGen Biotech, Inc. | Results NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting nkgenbiotech.com ↗
Flow cytometric analysis showed that NK cells (CD45+/CD56+/CD3-) were significantly increased in the groups administrated SNK01, while cytotoxic T cells (CD45+/CD3+/CD8+) in the cetuximab group decreased. |
| 2023-05-24 | Inmune Bio, Inc. | Results INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy inmunebio.com ↗
The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK. |
| 2023-05-11 | Wugen, Inc. | Results Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress wugen.com ↗
The oral presentation includes clinical data demonstrating the unique ability of memory-like natural killer cells to engage the adaptive immune system, and the potential for durable effectiveness in the relapsed or refractory (R/R) acute myeloid leukemia (AML) setting. |
| 2023-05-02 | NKGen Biotech, Inc. | Results NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting nkgenbiotech.com ↗
Dr. Gordon will present data from three rare cases of chemotherapy-resistant advanced soft tissue sarcomas (STS) which achieved durable partial responses and disease control with SNK01 plus an immune checkpoint inhibitor. |
| 2023-04-27 | Celularity Incorporated | Results Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia celularity.com ↗
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective response at Day 28 |
| 2023-04-19 | Wugen, Inc. | Results Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023 wugen.com ↗
Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) |
| 2023-03-30 | Mendus | Results Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit mendus.com ↗
The data presented today and at SITC 2022 demonstrate that DCOne cells drive strong expansion of memory NK cells, which subsequently can be used in different therapeutic applications. |
| 2022-12-12 | GT Biopharma, Inc. | Results GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 gtbiopharma.com ↗
In preclinical models, α3 MICA/B iNK cells demonstrated potent anti-leukemic activity against AML cell lines, and the kinetics of cytotoxicity were enhanced in combination with an anti-CD33 TriKE (GTB-3650). |
| 2022-12-11 | Wugen, Inc. | Results Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting wugen.com ↗
These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML. |
| 2022-11-10 | Phio Pharmaceuticals Inc. | Results Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th phiopharma.com ↗
The poster presentation discusses results from a pre-clinical study demonstrating that NK cells, when treated with PH-804, increased activation and enhanced the ability of NK cells to kill cancer cells. |
| 2022-11-08 | Mendus | Results Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes mendus.com ↗
STIMULATION WITH DCONE CELLS LEADS TO SELECTIVE AND STRONG >200-FOLD MEDIAN EXPANSION OF MEMORY NK CELLS |
| 2022-11-04 | Asher Biotherapeutics, Inc. | Results Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022 asherbio.com ↗
Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease, today announced new preclinical data demonstrating proof-of-concept for AB359 as a novel immunotherapy approach for chronic HBV. |
| 2022-11-03 | GT Biopharma, Inc. | Results GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting gtbiopharma.com ↗
Preclinical data to be presented demonstrate that iPSC-derived, MICA/B-targeted CAR NK cells induced potent activity against the AML cell line HL60, and that further enhancement of activity was achieved in combination with GTB-3650 through antibody-dependent cellular cytotoxicity. |
| 2022-09-26 | Celularity Incorporated | Results Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro celularity.com ↗
The study demonstrated how IAV sensitizes infected cells for targeting by CYNK-001 via multiple stress ligand and NK receptor activating pathways. |
| 2022-09-21 | NKGen Biotech, Inc. | Results NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma nkgenbiotech.com ↗
It is encouraging to see that Patient #1, despite being PD-L1 negative and having failed prior pembrolizumab, eventually showed a gradual tumor reduction with a 47% partial response, after which the patient underwent two surgical resections and achieved a sustained remission. |
| 2022-08-19 | NKMAX Co., Ltd. | Results 엔케이맥스, 비소세포폐암 임상 추적관찰 결과 국제학술지 게재 nkgenbiotechkorea.com ↗
논문에 따르면 슈퍼NK와 키트루다(성분명: 펨브롤리주맙) 병용투여군의 2년 시점의 전체 생존율(Overall Survival, OS)은 58.3%로 대조군인 키트루다 단독투여군 대비 41.6% 높았다. |
| 2022-05-26 | NKGen Biotech, Inc. | Results NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting nkgenbiotech.com ↗
SNK01 combined with avelumab showed efficacy in 17 advanced stage cancer patients (all heavily pre-treated with a median of 5 lines of prior therapy) |
| 2022-05-18 | Editas Medicine, Inc. | Results Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting editasmedicine.com ↗
Our SLEEK-edited, iPSC-derived double knock-in NK cells resulted in impressive tumor clearance, improved survival, and prolonged in vivo persistence in an ovarian cancer mouse model. |
| 2022-05-11 | NKMAX Co., Ltd. | Results 엔케이맥스, 육종암 말기 환자 완전 관해 "희귀성 난치암 시장 차 세대 면역세포치료제 기술 성장 기대" nkgenbiotechkorea.com ↗
엔케이맥스는 동정적 사용 승인을 통해 치료를 진행한 육종암 말기 환자에게서 암이 완전히 사라진 것으로 나타났다고 14일 밝혔다. |
| 2022-04-25 | Nkarta, Inc. | Results Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs nkartatx.com ↗
3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate) |
| 2022-04-23 | Nektar Therapeutics | Results Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® nektar.com ↗
NKTR-255 enhances anti-MCAM CAR NK cell cytotoxicity against Ewing sarcoma, osteosarcoma and neuroblastoma in vitro |
| 2022-04-08 | Hangzhou Qihan Biotech Co., Ltd. | Results Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022 qihanbio.com ↗
The data presented in one poster highlight the "Super NK" cells, genetically engineered with enhanced NK function, demonstrating superior killing capacity against blood and solid tumors. |
| 2022-04-08 | Editas Medicine, Inc. | Results Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting editasmedicine.com ↗
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach for solid tumors |
| 2022-03-09 | GT Biopharma, Inc. | Results GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 gtbiopharma.com ↗
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, presented preclinical data demonstrating its novel TriKE driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO's Targeted Anticancer Therapies Congress (TAT). |
| 2022-02-17 | Alkermes, Inc. | Results Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium alkermes.com ↗
Nemvaleukin monotherapy induced robust expansion of CD8+ T and natural killer (NK) cells, with minimal effect on regulatory T cells (Tregs). |
| 2022-02-15 | Celularity Incorporated | Regulatory Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers celularity.com ↗
Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer. |
| 2022-01-27 | NKMAX Co., Ltd. | Results 엔케이맥스, 난치성 육종암 환자의 종양 약 80% 관해 nkgenbiotechkorea.com ↗
그 결과 , 간문에 있던 종양의 크기가 61 X 35mm 에서 35 X 30mm 로 줄어들었고 간의 일부분에 퍼져 있던 종양의 크기가 51 X 37 mm 에서 16 X 7 mm 로 감소했다 . |
| 2021-12-17 | NKMAX Co., Ltd. | Results 엔케이맥스 “비소세포폐암 1/2a상 결과” 국제학술지 채택 nkgenbiotechkorea.com ↗
4 기 비소세포폐암 환자에게 슈퍼 NK 와 기존 T 세포 기반의 면역항암제를 병용 투여할 시 모든 유효성 평가변수에서 향상된 결과를 확인할 수 있었다 . |
| 2021-12-17 | NKMAX Co., Ltd. | Results 엔케이맥스, 비소세포폐암 임상 최종 결과 발표… 폐암에서도 효능 입증 nkgenbiotechkorea.com ↗
치료군의 질병통제율 (DCR; Disease Control Rate) 은 66.7% 로 키트루다 단독 대조군의 16.7% 의 수치와 비교해 우수한 항종양 효과를 보였다 . |
| 2021-12-13 | Celularity Incorporated | Results Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition celularity.com ↗ |
| 2021-12-12 | Editas Medicine, Inc. | Results Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting editasmedicine.com ↗
iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibody significantly reduce tumor burden |
| 2021-11-15 | NKGen Biotech, Inc. | Results NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting nkgenbiotech.com ↗
The results of the trial demonstrate that SNK01 can be safely combined with checkpoint inhibitors, resulting in meaningfully improved clinical outcomes, especially compared to the checkpoint inhibitor alone. |
| 2021-11-15 | Celularity Incorporated | Results Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting celularity.com ↗
The results demonstrate the synergistic effect of combining CYNK-101 with Cetuximab to drive antibody dependent cellular cytotoxicity activity against EGFR + tumors. |
| 2021-11-12 | Editas Medicine, Inc. | Results Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting editasmedicine.com ↗
The modifications resulted in improved serial tumor killing and dramatically increased NK cell persistence. |
| 2021-11-04 | Glycostem Therapeutics BV | Results Glycostem announces initial clinical data to be presented at 2021 ASH Annual Meeting glycostem.com ↗
Clearance of measurable residual disease seen in one patient for 6 months and in the second patient for 1 month after a single infusion of oNKord®, an off-the-shelf NK cell immunotherapy, in the lowest dose cohort |
| 2021-08-31 | NKMAX Co., Ltd. | Results 엔케이맥스, “NK세포치료제 최초로 고형암 말기 환자서 완전관해 나와” nkgenbiotechkorea.com ↗
이번 중간결과는 기존약물로 치료가 불가능한 수준의 육종암 (Sarcoma) 말기 암환자 13 명에 대한 우선 분석결과로 13 명 중 8 명이 치료효과를 보여 질병통제율 (DCR; Disease Control Rate) 은 61.5%(8/13) 이다 . |
| 2021-08-10 | Indapta Therapeutics, INC. | Results Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma – Results published in Blood Advances – SAN FRANCISCO, indapta.com ↗
Results from in vitro assays showed G-NK cells had six-fold higher anti-myeloma cell-killing activity compared with conventional NK cells when combined with the mAb daratumumab or elotuzumab (p<0.001). |
| 2021-08-03 | NKMAX Co., Ltd. | Results 엔케이맥스, 슈퍼NK 면역항암제 임상 1/2a상 첫 종료 선언 nkgenbiotechkorea.com ↗
회사 관계자는 ASCO2020 에서 발표한 우수한 중간결과와 유사하게 키트루다 단독투여군에 비해 키트루다 +SNK01 병용투여군에서 치료반응률 (ORR; Objective Response Rate) 이 우수했으며 , 통계적으로 유의미한 무진행생존기간 (PFS; Progression Free Survival) 증가를 보여주었다고 설명했다 . |
| 2021-07-07 | GT Biopharma, Inc. | Results GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota gtbiopharma.com ↗
TriKE™ improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model |
| 2021-06-04 | Alkermes, Inc. | Results Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting alkermes.com ↗ |
| 2021-04-08 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, ‘표적형 NK면역항암제’ 공동임상 미국FDA 승인 nkgenbiotechkorea.com ↗
엔케이맥스 ( 코스닥 182400) 는 아피메드 (Affimed NV) 와 공동으로 진행하는 ‘표적형 NK 면역항암제 ’ 미국 임상 1/2a 상 IND 승인을 완료했다고 1 일 밝혔다 . |
| 2021-03-31 | NKGen Biotech, Inc. | Regulatory Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors nkgenbiotech.com ↗ |
| 2021-03-17 | GT Biopharma, Inc. | Results GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results gtbiopharma.com ↗
Correlative studies have shown reproducible endogenous ("native") NK cell activity in all patients. |
| 2021-03-08 | GT Biopharma, Inc. | Results GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer gtbiopharma.com ↗
The ROR1 TriKE™ was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing of multiple prostate cancer cells including LnCAP, C4-2, PC-3, DU-145, VCaP and 22RV1. |
| 2021-03-03 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, TKI 내성 생긴 폐암환자 대상 한국임상 본격화 nkgenbiotechkorea.com ↗
엔케이맥스 ( 코스닥 182400) 는 자가 NK 세포 치료제인 슈퍼 NK(SNK01) 의 병용투여 국내 임상 1/2a 상의 IRB ( 기관윤리심의원회 ) 승인을 받았다고 3 일 밝혔다 . |
| 2021-01-07 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 폐암환자 치료에 새로운 기준 제시 nkgenbiotechkorea.com ↗
엔케이맥스 ( 코스닥 182400) 는 3 종 병용투여 국내 임상 1/2a 상의 한국 FDA 승인을 완료했다고 7 일 밝혔다 . |
| 2020-12-21 | GT Biopharma, Inc. | Results GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT gtbiopharma.com ↗
Targeted delivery of IL-15 to NK cells via GTB-3550 TriKE™ therapy showed preferential proliferation of NK cells, significantly less effect on CD8+ T-cells, and no observed toxicity at 25x the previous reported MTD for continuous infusion of recombinant human IL-15. |
| 2020-12-08 | GT Biopharma, Inc. | Results GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients gtbiopharma.com ↗
Correlative studies have shown reproducible NK cell activity in all patients. |
| 2020-12-07 | Nektar Therapeutics | Results Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting nektar.com ↗
In our studies, we found the novel IL-15 receptor agonist, NKTR-255, was effective in reverting the inhibitory status observed in NK cells from MM patients, leading to enhanced direct NK cytotoxicity against several MM c |
| 2020-11-11 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
Loss of NK cells reduces CD8+T cell percentages and function in the peripheral blood and in the tumor, suggesting a connection between early NK cell function and anti-tumor adaptive immune responses. |
| 2020-09-01 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 슈퍼NK 임상 미국FDA 특별 승인 nkgenbiotechkorea.com ↗
엔케이맥스가 면역관문억제제 키트루다 ( 펨브롤리주맙 ) 및 바벤시오 ( 아벨루맙 ) 를 병용투여하는 코호트 4 추가에 대해 미국 FDA 의 IND 승인을 완료하고 , 18 명의 환자 추가모집에 들어갈 예정이다 . |
| 2020-08-31 | NKGen Biotech, Inc. | Regulatory NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors. nkgenbiotech.com ↗ |
| 2020-08-11 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 알츠하이머 치료로 파이프라인 확대 nkgenbiotechkorea.com ↗
회사는 알츠하이머 환자를 대상으로 하는 임상 1 상 IND 승인을 완료했다고 11 일 밝혔다 . |
| 2020-06-22 | Nkarta, Inc. | Results Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II nkartatx.com ↗
TGFβR2 knockout CAR NK cells were resistant to TGFβ-mediated inhibition of tumor cell killing. |
| 2020-06-03 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 슈퍼NK+표적항암제 병용 임상1/2a상 美 FDA 승인 nkgenbiotechkorea.com ↗
엔케이맥스 ( 코스닥 182400, 대표이사 박상우 ) 는 미국 FDA 로부터 전이성 / 진행성 고형암 치료제 개발을 위한 슈퍼 NK(SNK01)+ 표적항암제 병용 임상 1/2a 상 승인을 받았다고 2 일 밝혔다 . |
| 2020-06-02 | NKGen Biotech, Inc. | Regulatory NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers nkgenbiotech.com ↗
the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for SNK01 in combination with trastuzumab (Herceptin) or cetuximab (Erbitux) for the treatment of advanced/metastatic HER2- or EGFR- expressing cancers. |
| 2020-06-01 | NKMAX Co., Ltd. | Results 엔케이맥스, 비소세포폐암 4기 ‘슈퍼NK’+키트루다 병용 우수한 결과 ASCO 발표 nkgenbiotechkorea.com ↗
병용투여군의 무진행생존기간 (PFS; Progression-Free Survival) 은 8 개월로 나타났고 p-value 값은 0.008 수준이다 . |
| 2020-05-29 | NKGen Biotech, Inc. | Results NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference nkgenbiotech.com ↗
Overall response rate (ORR) via RECIST 1.1 in the combination arm was 44% and significantly higher compared to Keytruda alone with an 8-month median progression free survival and a median overall survival that had not yet been met. |
| 2020-05-15 | NKMAX Co., Ltd. | Results 엔케이맥스, ‘슈퍼NK’ 종양 감소 반응률(ORR) 66%...ASCO 초록 공개 nkgenbiotechkorea.com ↗
약물 치료효과를 확인하는 객관적반응률 (ORR, Objective Response Rate) 은 66% 로 , 치료군 6 명 중 4 명에게서 종양 감소 효과를 보이는 우수한 결과가 나타났다 . |
| 2020-05-15 | Editas Medicine, Inc. | Results Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies editasmedicine.com ↗
The iNKs derived from the edited iPSC clones had enhanced tumor killing activity relative to iNKs from unedited iPSCs, demonstrating the utility of an edited iPSC platform. |
| 2020-05-14 | Phio Pharmaceuticals Inc. | Results Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 phiopharma.com ↗
We have shown that our INTASYL technology is able to reprogram immune cells, such as T cells or NK cells, and thereby significantly improve their cell killing activity. |
| 2020-05-06 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 표적항암제 병용 임상 美 FDA IND 신청 완료 nkgenbiotechkorea.com ↗ |
| 2020-04-22 | NKMAX Co., Ltd. | Results 고가 면역항암제 투여 여부 결정에 ‘엔케이뷰키트’ 활용 nkgenbiotechkorea.com ↗
약물 반응군의 NK 세포 활성도는 1433.25 pg/ml, 비반응군은 84.50 pg/ml 로 현격한 수치 차이를 보였다 . |
| 2020-03-17 | AvenCell Europe GmbH | Results GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified off-the-shelf Natural Killer Cells in “Nature Scientific Reports” avencell.com ↗
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced that “Nature Scientific Reports” has published pre-clinical proof-of-concept data on UniCAR-modified off-the-shelf Natural Killer (NK) cells targeting GD2-expressing tumors (Mitwasi et al. 2020, 10:2141). |
| 2020-03-04 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 슈퍼NK 면역항암제 최대 허용 용량 결정을 위한 임상 진행 nkgenbiotechkorea.com ↗
본 임상시험은 안전성을 확인하는 임상 1 상으로 , MFDS( 식품의약품안전처 ) 로부터 IND( 임상시험계획 ) 승인을 완료했다 . |
| 2020-01-21 | GT Biopharma, Inc. | Results GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives gtbiopharma.com ↗
The data demonstrated that natural killer (NK) cells are stimulated by the human IL-15 cytokine portion of the TriKE™ molecule which provided a self-sustaining signal, activating NK cells and enhancing their ability to kill. |
| 2019-12-09 | Nektar Therapeutics | Results Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting nektar.com ↗
Treatment with NKTR-255 enhanced the number and function of both NK and CD8+ effector memory T cell populations in peripheral blood from healthy donors and MM patients in a dose dependent manner. |
| 2019-11-19 | Selecxine | Results TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity selecxine.com ↗
Among them, the hIL-2/TCB2 complex (hIL-2/TCB2c) exerted the best efficacy by inducing a prodigious expansion of host memory phenotype (MP) CD8 T (60-fold) and NK cells (18-fold) with less efficient Treg proliferation (5-fold). |
| 2019-10-03 | GT Biopharma, Inc. | Results GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells gtbiopharma.com ↗
Research findings from Dr. Schacker's and Dr. Miller's laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE™. |
| 2019-06-27 | Inmune Bio, Inc. | Results INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE inmunebio.com ↗
The paper identifies a unique signaling “fingerprint” expressed by NK cells after binding to CTV-1 tumor cells, which is the parent clone of INmune Bio’s own INB16 cells. |
| 2019-06-14 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, ‘슈퍼NK’ 면역항암제 美 FDA 임상 1상 계획서 제출 완료 nkgenbiotechkorea.com ↗
엔케이맥스(대표 조용환)는 슈퍼NK 면역항암제의 임상 계획서를 미국 현지 시각으로 14일 미국 FDA에 제출 완료하였다고 밝혔다. |
| 2019-04-01 | Nkarta, Inc. | Results Nkarta Therapeutics Presents Data at Aacr Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity Of NK Cells nkartatx.com ↗
The data showed that Nkarta’s methods for NK cell expansion and engineering consistently generate cells with sustained, elevated phenotypic markers of cell activation, enhanced tumor recognition, resistance to apoptosis and potent cytotoxicity. |
| 2019-03-05 | NKGen Biotech, Inc. | Regulatory NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer nkgenbiotech.com ↗ |
| 2018-11-09 | Nkarta, Inc. | Results Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity In Preclinical Tumor Model nkartatx.com ↗
In a challenging xenograft osteosarcoma model, a single injection of Nkarta’s NK cells resulted in dramatic tumor shrinkage and complete suppression of the tumor for over 2 months. |
| 2018-11-09 | Alligator Bioscience AB | Results Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting alligatorbioscience.se ↗
The preclinical data show that ALG.APV-527 localizes to 5T4 positive tumors and selectively stimulates and enhances tumor-directed T cell and NK cell responses, displaying potent anti-tumor effects. |
| 2017-05-30 | 4SC AG | Results Resminostat enhances immune cell cancer cell interaction 4sc.com ↗
We now demonstrated that treatment with resminostat enhanced the activity of NK cells. |
| 2017-04-02 | Genprex, Inc. | Results Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer genprex.com ↗
The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice. |
| 2017-03-02 | Fate Therapeutics | Results Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting fatetherapeutics.com ↗ |
| 2016-05-16 | Fate Therapeutics | Results Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy fatetherapeutics.com ↗
Scientists from Fate Therapeutics and the University of Minnesota demonstrated through in vivo and in vitro preclinical studies that Adaptive NK cells exhibit enhanced persistence and deliver potent anti-tumor activity alone and in combination with therapeutic monoclonal antibodies. |
| 2015-02-17 | Halozyme Therapeutics | Results Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics halozyme.com ↗
PEGPH20 enhances HA-high breast cancer cell killing by trastuzumab and natural killer (NK) cells in vitro. |
All press releases naming this drug 130 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 130 releases opens the full record — a long page | ||
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK cells | “This study aims to test whether haploidentical NK cells from healthy individuals, expanded and activated in vitro, administered when the disease is nearly eradicated by...” NCT06783478 ↗49“NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies.” NCT03554889 ↗ “The NK cells will be collected from the donor's blood and then processed using an experimental device called a CliniMACS device.” NCT00698009 ↗ “NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.” NCT04209712 ↗ “Natural killer (NK) cells are one of the main type of immune cells that mediate the graft-versus-leukemia (GVL) effect.” NCT03348033 ↗ “NK cells were expanded ex vivo from autologous peripheral blood, allogeneic peripheral blood, or umbilical cord blood.” NCT02851784 ↗ “The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center.” NCT00660166 ↗ “Donor NK cells were purified and cultured ex vivo with IL-2 before infusion, at three dose levels.” PMID 34071607 ↗ May 2021 “Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells” NCT05143125 ↗ “All patients received both sintilimab 200mg and 3×109 NK cells every 3 weeks.” PMID 36569881 ↗ Dec 2022 “Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).” NCT05272293 ↗ |
| Known as | IL-2 NK | “prophylactic donor-derived ex vivo IL-2 activated NK cell (IL-2 NK) infusion after allo-HSCT for patients with hematologic malignancies.” PMID 34071607 ↗ May 2021 |
| Known as | natural killer (NK) cells | “received highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor-ligand mismatched donors” PMID 21791425 ↗ Jul 20115“We are trying to achieve a similar result using a less complex and less costly approach, with Natural Killer (NK) cells.” NCT00717184 ↗ “The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center.” NCT00660166 ↗ “Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells.” NCT00720785 ↗ “the combined therapy using cryosurgery and natural killer (NK) cells” NCT02849366 ↗ “Natural Killer (NK) Cells” NCT03242603 ↗ |
| Known as | Natural killer cells | “Natural killer cells are blood cells that are responsible for eliminating cancer cells especially when there are only a few.” NCT00660166 ↗3“infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia” NCT04578210 ↗ “Natural killer cells (NK cells) have MHC-unrestricted killing effect on malignant tumor cells” NCT02399735 ↗ “Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells” NCT05143125 ↗ |
| Known as | nature killer(NK) cells | “The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd” NCT02718859 ↗ |
| Action | Deplete | “They can recognize and kill abnormal cells in the body” NCT00526292 ↗ |
| Modality | Cell therapy | “natural killer (NK) cell infusion” NCT00526292 ↗ |
| Route | Intravenous | “The NK cells will be given to the subject intravenously (into a vein).” NCT00660166 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT07411599 ↗ |